INCOBOTULINUMTOXINA
Parkinson's Disease
Merz Pharmaceuticals GmbHprotein_peptidePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 67/ 100
- Competitive Position
- 73/ 100
Competitive context
52 Active assets in the Parkinson's Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tvp-1012 Guangzhou Henovcom Bioscience Co. Ltd. | Phase 4 | BBB |
Istradefylline Georgetown University | Phase 4 | BBB |
carbidopa Tanta University | Phase 4 | BBB |
LEVODOPA Ihab Elsayed Hassan | Phase 4 | BBB |
Sra-333 University of Virginia | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
INCOBOTULINUMTOXINA is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →